Sentinel Lymph Node Biopsy for Patients With cN1 HR+/HER2− Breast Cancer and Palpable Adenopathy

What is the feasibility of upfront sentinel lymph node biopsy (SLNB) and the rate of axillary lymph node dissection (ALND) among patients with HR+/HER2− cN1 breast cancer selected with axillary ultrasound?In this nonrandomized clinical trial including 78 consecutive patients with cTx/cT1-2 cN1 HR+/HER2− breast cancer with palpable, biopsy-proven nodal metastases, SLNB was feasible among patients with cN1 HR+/HER2− disease, with 3 or more SLNs retrieved in 96% of cases, and nearly 70% of patients meeting criteria for SLNB alone and able to avoid ALND.This approach affords the opportunity to omit ALND and minimize morbidity among cN1 patients with limited nodal disease burden.

Corresponding Author: Anita Mamtani, MD, Breast Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, 300 E 66th St, New York, NY 10065 (mamtana1@mskcc.org).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.